APO Research
Talk to an analyst

APO RESEARCH · REPORT

Neurodegenerative Disease IVD

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Neurodegenerative Disease IVD Market Outlook and Growth Opportunities 2026

16 April 2026Not stated

Choose your research edition.

Industry ResearchNeurodegenerative Disease IVD Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Neurodegenerative Disease IVD Industry Growth and Trends Forecast to 203286 pages · $3,450 USDMarket StructureGlobal Neurodegenerative Disease IVD Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032180 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neurodegenerative Disease IVD Market Outlook and Growth Opportunities 2026$4,250 USDMarket Analysis & ForecastGlobal Neurodegenerative Disease IVD Market Analysis and Forecast 2026-2032225 pages · $4,950 USD

Market perspective

The global Neurodegenerative Disease IVD market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Neurodegenerative Disease IVD is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Neurodegenerative Disease IVD is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Neurodegenerative Disease IVD is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Neurodegenerative Disease IVD market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Neurodegenerative Disease IVD market include ADx Neurosciences, Analytik Jena, Beckman Coulter, Creative Biolabs, Fujirebio, Genemedi, Medix Biochemica, Revvity and Roche Diagnostics, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Neurodegenerative Disease IVD market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Neurodegenerative Disease IVD and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Neurodegenerative Disease IVD revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Neurodegenerative Disease IVD market.

Neurodegenerative Disease IVD Segment by Company

ADx Neurosciences

Analytik Jena

Beckman Coulter

Creative Biolabs

Fujirebio

Genemedi

Medix Biochemica

Revvity

Roche Diagnostics

Neurodegenerative Disease IVD Segment by Type

Protein Biomarker Detection

Nucleic Acid Biomarker Detection

Others

Neurodegenerative Disease IVD Segment by Application

Alzheimer's Disease

Parkinson's Disease

Huntington's Disease

Amyotrophic Lateral Sclerosis (ALS)

Multiple System Atrophy (MSA)

Progressive Supranuclear Palsy (PSP)

Others

Neurodegenerative Disease IVD Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Neurodegenerative Disease IVD status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Neurodegenerative Disease IVD key companies, revenue, market share, and recent developments.

3. To split the Neurodegenerative Disease IVD breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Neurodegenerative Disease IVD market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Neurodegenerative Disease IVD significant trends, drivers, influence factors in global and regions.

6. To analyze Neurodegenerative Disease IVD competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neurodegenerative Disease IVD market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neurodegenerative Disease IVD and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neurodegenerative Disease IVD.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Neurodegenerative Disease IVD industry.

Chapter 3: Detailed analysis of Neurodegenerative Disease IVD company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Neurodegenerative Disease IVD in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Neurodegenerative Disease IVD in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Neurodegenerative Disease IVD Industry Trends Table 2. Neurodegenerative Disease IVD Industry Drivers Table 3. Neurodegenerative Disease IVD Industry Opportunities and Challenges Table 4. Neurodegenerative Disease IVD Industry Restraints Table 5. Global Neurodegenerative Disease IVD Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Neurodegenerative Disease IVD Revenue Share by Company (2021-2026) Table 7. Global Neurodegenerative Disease IVD Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Neurodegenerative Disease IVD Key Company Manufacturing Base & Headquarters Table 9. Global Neurodegenerative Disease IVD Company, Product Type & Application Table 10. Global Neurodegenerative Disease IVD Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Neurodegenerative Disease IVD by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Protein Biomarker Detection Table 15. Significant Companies of Nucleic Acid Biomarker Detection Table 16. Significant Companies of Others Table 17. Global Neurodegenerative Disease IVD Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Neurodegenerative Disease IVD Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Neurodegenerative Disease IVD Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Neurodegenerative Disease IVD Sales Value Share by Type (2021-2026) Table 21. Global Neurodegenerative Disease IVD Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Alzheimer's Disease Table 23. Significant Companies of Parkinson's Disease Table 24. Significant Companies of Huntington's Disease Table 25. Significant Companies of Amyotrophic Lateral Sclerosis (ALS) Table 26. Significant Companies of Multiple System Atrophy (MSA) Table 27. Significant Companies of Progressive Supranuclear Palsy (PSP) Table 28. Significant Companies of Others Table 29. Global Neurodegenerative Disease IVD Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Neurodegenerative Disease IVD Sales Value by Application (2021-2026) & (US$ Million) Table 31. Global Neurodegenerative Disease IVD Sales Value by Application (2027-2032) & (US$ Million) Table 32. Global Neurodegenerative Disease IVD Sales Value Share by Application (2021-2026) Table 33. Global Neurodegenerative Disease IVD Sales Value Share by Application (2027-2032) Table 34. Global Neurodegenerative Disease IVD Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Neurodegenerative Disease IVD Sales Value by Region (2021-2026) & (US$ Million) Table 36. Global Neurodegenerative Disease IVD Sales Value Share by Region (2021-2026) Table 37. Global Neurodegenerative Disease IVD Sales Value by Region (2027-2032) & (US$ Million) Table 38. Global Neurodegenerative Disease IVD Sales Value Share by Region (2027-2032) Table 39. Global Neurodegenerative Disease IVD Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Neurodegenerative Disease IVD Sales Value by Country (2021-2026) & (US$ Million) Table 41. Global Neurodegenerative Disease IVD Sales Value Market Share by Country (2021-2026) Table 42. Global Neurodegenerative Disease IVD Sales Value by Country (2027-2032) & (US$ Million) Table 43. Global Neurodegenerative Disease IVD Sales Value Market Share by Country (2027-2032) Table 44. ADx Neurosciences Company Information Table 45. ADx Neurosciences Business Overview Table 46. ADx Neurosciences Neurodegenerative Disease IVD Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. ADx Neurosciences Neurodegenerative Disease IVD Product Portfolio Table 48. ADx Neurosciences Recent Development Table 49. Analytik Jena Company Information Table 50. Analytik Jena Business Overview Table 51. Analytik Jena Neurodegenerative Disease IVD Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Analytik Jena Neurodegenerative Disease IVD Product Portfolio Table 53. Analytik Jena Recent Development Table 54. Beckman Coulter Company Information Table 55. Beckman Coulter Business Overview Table 56. Beckman Coulter Neurodegenerative Disease IVD Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Beckman Coulter Neurodegenerative Disease IVD Product Portfolio Table 58. Beckman Coulter Recent Development Table 59. Creative Biolabs Company Information Table 60. Creative Biolabs Business Overview Table 61. Creative Biolabs Neurodegenerative Disease IVD Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Creative Biolabs Neurodegenerative Disease IVD Product Portfolio Table 63. Creative Biolabs Recent Development Table 64. Fujirebio Company Information Table 65. Fujirebio Business Overview Table 66. Fujirebio Neurodegenerative Disease IVD Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Fujirebio Neurodegenerative Disease IVD Product Portfolio Table 68. Fujirebio Recent Development Table 69. Genemedi Company Information Table 70. Genemedi Business Overview Table 71. Genemedi Neurodegenerative Disease IVD Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Genemedi Neurodegenerative Disease IVD Product Portfolio Table 73. Genemedi Recent Development Table 74. Medix Biochemica Company Information Table 75. Medix Biochemica Business Overview Table 76. Medix Biochemica Neurodegenerative Disease IVD Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Medix Biochemica Neurodegenerative Disease IVD Product Portfolio Table 78. Medix Biochemica Recent Development Table 79. Revvity Company Information Table 80. Revvity Business Overview Table 81. Revvity Neurodegenerative Disease IVD Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Revvity Neurodegenerative Disease IVD Product Portfolio Table 83. Revvity Recent Development Table 84. Roche Diagnostics Company Information Table 85. Roche Diagnostics Business Overview Table 86. Roche Diagnostics Neurodegenerative Disease IVD Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Roche Diagnostics Neurodegenerative Disease IVD Product Portfolio Table 88. Roche Diagnostics Recent Development Table 89. Research Programs/Design for This Report Table 90. Authors List of This Report Table 91. Secondary Sources Table 92. Primary Sources List of Figures Figure 1. Neurodegenerative Disease IVD Product Image Figure 2. Global Neurodegenerative Disease IVD Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Neurodegenerative Disease IVD Market Size (2021-2032) & (US$ Million) Figure 4. Global Neurodegenerative Disease IVD Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Protein Biomarker Detection Image Figure 8. Nucleic Acid Biomarker Detection Image Figure 9. Others Image Figure 10. Global Neurodegenerative Disease IVD Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Neurodegenerative Disease IVD Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Neurodegenerative Disease IVD Sales Value Share by Type (2021-2032) Figure 13. Alzheimer's Disease Image Figure 14. Parkinson's Disease Image Figure 15. Huntington's Disease Image Figure 16. Amyotrophic Lateral Sclerosis (ALS) Image Figure 17. Multiple System Atrophy (MSA) Image Figure 18. Progressive Supranuclear Palsy (PSP) Image Figure 19. Others Image Figure 20. Global Neurodegenerative Disease IVD Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Neurodegenerative Disease IVD Sales Value Share 2021 VS 2025 VS 2032 Figure 22. Global Neurodegenerative Disease IVD Sales Value Share by Application (2021-2032) Figure 23. Global Neurodegenerative Disease IVD Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 24. Global Neurodegenerative Disease IVD Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 25. North America Neurodegenerative Disease IVD Sales Value (2021-2032) & (US$ Million) Figure 26. North America Neurodegenerative Disease IVD Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Europe Neurodegenerative Disease IVD Sales Value (2021-2032) & (US$ Million) Figure 28. Europe Neurodegenerative Disease IVD Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Asia-Pacific Neurodegenerative Disease IVD Sales Value (2021-2032) & (US$ Million) Figure 30. Asia-Pacific Neurodegenerative Disease IVD Sales Value Share by Country (%), 2025 VS 2032 Figure 31. South America Neurodegenerative Disease IVD Sales Value (2021-2032) & (US$ Million) Figure 32. South America Neurodegenerative Disease IVD Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Middle East & Africa Neurodegenerative Disease IVD Sales Value (2021-2032) & (US$ Million) Figure 34. Middle East & Africa Neurodegenerative Disease IVD Sales Value Share by Country (%), 2025 VS 2032 Figure 35. USA Neurodegenerative Disease IVD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. USA Neurodegenerative Disease IVD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. USA Neurodegenerative Disease IVD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Canada Neurodegenerative Disease IVD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Canada Neurodegenerative Disease IVD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Canada Neurodegenerative Disease IVD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Mexico Neurodegenerative Disease IVD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Mexico Neurodegenerative Disease IVD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Mexico Neurodegenerative Disease IVD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Germany Neurodegenerative Disease IVD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Germany Neurodegenerative Disease IVD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Germany Neurodegenerative Disease IVD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. France Neurodegenerative Disease IVD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. France Neurodegenerative Disease IVD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. France Neurodegenerative Disease IVD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. U.K. Neurodegenerative Disease IVD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. U.K. Neurodegenerative Disease IVD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. U.K. Neurodegenerative Disease IVD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Italy Neurodegenerative Disease IVD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Italy Neurodegenerative Disease IVD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Italy Neurodegenerative Disease IVD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Spain Neurodegenerative Disease IVD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Spain Neurodegenerative Disease IVD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Spain Neurodegenerative Disease IVD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Russia Neurodegenerative Disease IVD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Russia Neurodegenerative Disease IVD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Russia Neurodegenerative Disease IVD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Netherlands Neurodegenerative Disease IVD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Netherlands Neurodegenerative Disease IVD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Netherlands Neurodegenerative Disease IVD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Nordic Countries Neurodegenerative Disease IVD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Nordic Countries Neurodegenerative Disease IVD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Nordic Countries Neurodegenerative Disease IVD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. China Neurodegenerative Disease IVD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. China Neurodegenerative Disease IVD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. China Neurodegenerative Disease IVD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Japan Neurodegenerative Disease IVD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Japan Neurodegenerative Disease IVD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Japan Neurodegenerative Disease IVD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. South Korea Neurodegenerative Disease IVD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. South Korea Neurodegenerative Disease IVD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. South Korea Neurodegenerative Disease IVD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. India Neurodegenerative Disease IVD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. India Neurodegenerative Disease IVD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. India Neurodegenerative Disease IVD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Australia Neurodegenerative Disease IVD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Australia Neurodegenerative Disease IVD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Australia Neurodegenerative Disease IVD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Southeast Asia Neurodegenerative Disease IVD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Southeast Asia Neurodegenerative Disease IVD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Southeast Asia Neurodegenerative Disease IVD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Brazil Neurodegenerative Disease IVD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Brazil Neurodegenerative Disease IVD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Brazil Neurodegenerative Disease IVD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Argentina Neurodegenerative Disease IVD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Argentina Neurodegenerative Disease IVD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Argentina Neurodegenerative Disease IVD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Chile Neurodegenerative Disease IVD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Chile Neurodegenerative Disease IVD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Chile Neurodegenerative Disease IVD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Colombia Neurodegenerative Disease IVD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Colombia Neurodegenerative Disease IVD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Colombia Neurodegenerative Disease IVD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Peru Neurodegenerative Disease IVD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Peru Neurodegenerative Disease IVD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Peru Neurodegenerative Disease IVD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Neurodegenerative Disease IVD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Saudi Arabia Neurodegenerative Disease IVD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Saudi Arabia Neurodegenerative Disease IVD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Israel Neurodegenerative Disease IVD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Israel Neurodegenerative Disease IVD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Israel Neurodegenerative Disease IVD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. UAE Neurodegenerative Disease IVD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. UAE Neurodegenerative Disease IVD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. UAE Neurodegenerative Disease IVD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Turkey Neurodegenerative Disease IVD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Turkey Neurodegenerative Disease IVD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Turkey Neurodegenerative Disease IVD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Iran Neurodegenerative Disease IVD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Iran Neurodegenerative Disease IVD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Iran Neurodegenerative Disease IVD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Egypt Neurodegenerative Disease IVD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Egypt Neurodegenerative Disease IVD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Egypt Neurodegenerative Disease IVD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Years Considered Figure 120. Research Process Figure 121. Key Executives Interviewed

Scope & coverage.

Types
  • Protein Biomarker Detection
  • Nucleic Acid Biomarker Detection
  • Others
Applications
  • Alzheimer's Disease
  • Parkinson's Disease
  • Huntington's Disease
  • Amyotrophic Lateral Sclerosis (ALS)
  • Multiple System Atrophy (MSA)
  • Progressive Supranuclear Palsy (PSP)
  • Others
Companies covered
  • ADx Neurosciences
  • Analytik Jena
  • Beckman Coulter
  • Creative Biolabs
  • Fujirebio
  • Genemedi
  • Medix Biochemica
  • Revvity
  • Roche Diagnostics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Neurodegenerative Disease IVD Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Neurodegenerative Disease IVD Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Neurodegenerative Disease IVD Market Dynamics
  1. 2.1 Neurodegenerative Disease IVD Industry Trends
  2. 2.2 Neurodegenerative Disease IVD Industry Drivers
  3. 2.3 Neurodegenerative Disease IVD Industry Opportunities and Challenges
  4. 2.4 Neurodegenerative Disease IVD Industry Restraints
3 Neurodegenerative Disease IVD Market by Company
  1. 3.1 Global Neurodegenerative Disease IVD Company Revenue Ranking in 2025
  2. 3.2 Global Neurodegenerative Disease IVD Revenue by Company (2021-2026)
  3. 3.3 Global Neurodegenerative Disease IVD Company Ranking (2024-2026)
  4. 3.4 Global Neurodegenerative Disease IVD Company Manufacturing Base and Headquarters
  5. 3.5 Global Neurodegenerative Disease IVD Company Product Type and Application
  6. 3.6 Global Neurodegenerative Disease IVD Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Neurodegenerative Disease IVD Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Neurodegenerative Disease IVD Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Neurodegenerative Disease IVD Market by Type
  1. 4.1 Neurodegenerative Disease IVD Type Introduction
  2. 4.1.1 Protein Biomarker Detection
  3. 4.1.2 Nucleic Acid Biomarker Detection
  4. 4.1.3 Others
  5. 4.2 Global Neurodegenerative Disease IVD Sales Value by Type
  6. 4.2.1 Global Neurodegenerative Disease IVD Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Neurodegenerative Disease IVD Sales Value by Type (2021-2032)
  8. 4.2.3 Global Neurodegenerative Disease IVD Sales Value Share by Type (2021-2032)
5 Neurodegenerative Disease IVD Market by Application
  1. 5.1 Neurodegenerative Disease IVD Application Introduction
  2. 5.1.1 Alzheimer's Disease
  3. 5.1.2 Parkinson's Disease
  4. 5.1.3 Huntington's Disease
  5. 5.1.4 Amyotrophic Lateral Sclerosis (ALS)
  6. 5.1.5 Multiple System Atrophy (MSA)
  7. 5.1.6 Progressive Supranuclear Palsy (PSP)
  8. 5.1.7 Others
  9. 5.2 Global Neurodegenerative Disease IVD Sales Value by Application
  10. 5.2.1 Global Neurodegenerative Disease IVD Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.2.2 Global Neurodegenerative Disease IVD Sales Value by Application (2021-2032)
  12. 5.2.3 Global Neurodegenerative Disease IVD Sales Value Share by Application (2021-2032)
6 Neurodegenerative Disease IVD Regional Value Analysis
  1. 6.1 Global Neurodegenerative Disease IVD Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Neurodegenerative Disease IVD Sales Value by Region (2021-2032)
  3. 6.2.1 Global Neurodegenerative Disease IVD Sales Value by Region: 2021-2026
  4. 6.2.2 Global Neurodegenerative Disease IVD Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Neurodegenerative Disease IVD Sales Value (2021-2032)
  7. 6.3.2 North America Neurodegenerative Disease IVD Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Neurodegenerative Disease IVD Sales Value (2021-2032)
  10. 6.4.2 Europe Neurodegenerative Disease IVD Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Neurodegenerative Disease IVD Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Neurodegenerative Disease IVD Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Neurodegenerative Disease IVD Sales Value (2021-2032)
  16. 6.6.2 South America Neurodegenerative Disease IVD Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Neurodegenerative Disease IVD Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Neurodegenerative Disease IVD Sales Value Share by Country, 2025 VS 2032
7 Neurodegenerative Disease IVD Country-level Value Analysis
  1. 7.1 Global Neurodegenerative Disease IVD Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Neurodegenerative Disease IVD Sales Value by Country (2021-2032)
  3. 7.2.1 Global Neurodegenerative Disease IVD Sales Value by Country (2021-2026)
  4. 7.2.2 Global Neurodegenerative Disease IVD Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Neurodegenerative Disease IVD Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Neurodegenerative Disease IVD Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Neurodegenerative Disease IVD Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Neurodegenerative Disease IVD Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Neurodegenerative Disease IVD Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Neurodegenerative Disease IVD Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Neurodegenerative Disease IVD Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Neurodegenerative Disease IVD Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Neurodegenerative Disease IVD Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Neurodegenerative Disease IVD Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Neurodegenerative Disease IVD Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Neurodegenerative Disease IVD Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Neurodegenerative Disease IVD Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Neurodegenerative Disease IVD Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Neurodegenerative Disease IVD Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Neurodegenerative Disease IVD Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Neurodegenerative Disease IVD Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Neurodegenerative Disease IVD Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Neurodegenerative Disease IVD Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Neurodegenerative Disease IVD Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Neurodegenerative Disease IVD Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Neurodegenerative Disease IVD Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Neurodegenerative Disease IVD Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Neurodegenerative Disease IVD Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Neurodegenerative Disease IVD Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Neurodegenerative Disease IVD Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Neurodegenerative Disease IVD Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Neurodegenerative Disease IVD Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Neurodegenerative Disease IVD Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Neurodegenerative Disease IVD Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Neurodegenerative Disease IVD Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Neurodegenerative Disease IVD Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Neurodegenerative Disease IVD Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Neurodegenerative Disease IVD Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Neurodegenerative Disease IVD Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Neurodegenerative Disease IVD Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Neurodegenerative Disease IVD Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Neurodegenerative Disease IVD Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Neurodegenerative Disease IVD Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Neurodegenerative Disease IVD Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Neurodegenerative Disease IVD Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Neurodegenerative Disease IVD Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Neurodegenerative Disease IVD Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Neurodegenerative Disease IVD Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Neurodegenerative Disease IVD Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Neurodegenerative Disease IVD Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Neurodegenerative Disease IVD Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Neurodegenerative Disease IVD Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Neurodegenerative Disease IVD Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Neurodegenerative Disease IVD Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Neurodegenerative Disease IVD Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Neurodegenerative Disease IVD Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Neurodegenerative Disease IVD Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Neurodegenerative Disease IVD Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Neurodegenerative Disease IVD Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Neurodegenerative Disease IVD Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Neurodegenerative Disease IVD Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Neurodegenerative Disease IVD Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Neurodegenerative Disease IVD Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Neurodegenerative Disease IVD Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Neurodegenerative Disease IVD Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Neurodegenerative Disease IVD Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Neurodegenerative Disease IVD Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Neurodegenerative Disease IVD Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Neurodegenerative Disease IVD Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Neurodegenerative Disease IVD Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Neurodegenerative Disease IVD Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Neurodegenerative Disease IVD Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Neurodegenerative Disease IVD Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Neurodegenerative Disease IVD Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Neurodegenerative Disease IVD Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Neurodegenerative Disease IVD Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Neurodegenerative Disease IVD Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Neurodegenerative Disease IVD Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Neurodegenerative Disease IVD Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Neurodegenerative Disease IVD Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Neurodegenerative Disease IVD Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Neurodegenerative Disease IVD Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Neurodegenerative Disease IVD Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Neurodegenerative Disease IVD Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Neurodegenerative Disease IVD Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Neurodegenerative Disease IVD Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Neurodegenerative Disease IVD Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Neurodegenerative Disease IVD Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 ADx Neurosciences
  2. 8.1.1 ADx Neurosciences Company Information
  3. 8.1.2 ADx Neurosciences Business Overview
  4. 8.1.3 ADx Neurosciences Neurodegenerative Disease IVD Revenue and Gross Margin (2021-2026)
  5. 8.1.4 ADx Neurosciences Neurodegenerative Disease IVD Product Portfolio
  6. 8.1.5 ADx Neurosciences Recent Developments
  7. 8.2 Analytik Jena
  8. 8.2.1 Analytik Jena Company Information
  9. 8.2.2 Analytik Jena Business Overview
  10. 8.2.3 Analytik Jena Neurodegenerative Disease IVD Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Analytik Jena Neurodegenerative Disease IVD Product Portfolio
  12. 8.2.5 Analytik Jena Recent Developments
  13. 8.3 Beckman Coulter
  14. 8.3.1 Beckman Coulter Company Information
  15. 8.3.2 Beckman Coulter Business Overview
  16. 8.3.3 Beckman Coulter Neurodegenerative Disease IVD Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Beckman Coulter Neurodegenerative Disease IVD Product Portfolio
  18. 8.3.5 Beckman Coulter Recent Developments
  19. 8.4 Creative Biolabs
  20. 8.4.1 Creative Biolabs Company Information
  21. 8.4.2 Creative Biolabs Business Overview
  22. 8.4.3 Creative Biolabs Neurodegenerative Disease IVD Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Creative Biolabs Neurodegenerative Disease IVD Product Portfolio
  24. 8.4.5 Creative Biolabs Recent Developments
  25. 8.5 Fujirebio
  26. 8.5.1 Fujirebio Company Information
  27. 8.5.2 Fujirebio Business Overview
  28. 8.5.3 Fujirebio Neurodegenerative Disease IVD Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Fujirebio Neurodegenerative Disease IVD Product Portfolio
  30. 8.5.5 Fujirebio Recent Developments
  31. 8.6 Genemedi
  32. 8.6.1 Genemedi Company Information
  33. 8.6.2 Genemedi Business Overview
  34. 8.6.3 Genemedi Neurodegenerative Disease IVD Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Genemedi Neurodegenerative Disease IVD Product Portfolio
  36. 8.6.5 Genemedi Recent Developments
  37. 8.7 Medix Biochemica
  38. 8.7.1 Medix Biochemica Company Information
  39. 8.7.2 Medix Biochemica Business Overview
  40. 8.7.3 Medix Biochemica Neurodegenerative Disease IVD Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Medix Biochemica Neurodegenerative Disease IVD Product Portfolio
  42. 8.7.5 Medix Biochemica Recent Developments
  43. 8.8 Revvity
  44. 8.8.1 Revvity Company Information
  45. 8.8.2 Revvity Business Overview
  46. 8.8.3 Revvity Neurodegenerative Disease IVD Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Revvity Neurodegenerative Disease IVD Product Portfolio
  48. 8.8.5 Revvity Recent Developments
  49. 8.9 Roche Diagnostics
  50. 8.9.1 Roche Diagnostics Company Information
  51. 8.9.2 Roche Diagnostics Business Overview
  52. 8.9.3 Roche Diagnostics Neurodegenerative Disease IVD Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Roche Diagnostics Neurodegenerative Disease IVD Product Portfolio
  54. 8.9.5 Roche Diagnostics Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst